TTYH3

Across TCGA pan-cancer cohorts, TTYH3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TTYH3 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TTYH3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TTYH3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where TTYH3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.727	0.915	.021	13	view →
CCRCC	OS	Tertile	All	1.000	0.896	.025	5	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	4	view →
HNSC	OS	Median	III,IV	0.945	1.000	.040	2	view →
GBM	DFS	Quartile	All	0.896	0.680	.009	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TTYH3–PDAC (OS)

Open the PDAC breakdown →